Methods for the administration of certain VMAT2 inhibitors

  • US 10,857,148 B2
  • Filed: 05/11/2020
  • Issued: 12/08/2020
  • Est. Priority Date: 10/10/2017
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating a patient with tardive dyskinesia, wherein the patient is also being co-administered digoxin, comprising:

  • (a) administering to the patient a therapeutically effective amount of a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3 sobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester, (+)-α

    -3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, and pharmaceutically acceptable salts and isotopic variants thereof,(b) monitoring the digoxin concentration in the patient'"'"'s blood; and

    (c) reducing the dose of digoxin when the digoxin exposure in the patient'"'"'s blood is increased as compared with the digoxin level in a patient who is administered digoxin alone.

View all claims

    Thank you for your feedback